Log in

NASDAQ:CMRX - Chimerix Stock Price, Forecast & News

$2.04
-0.03 (-1.45 %)
(As of 01/17/2020 04:00 PM ET)
Today's Range
$2.02
Now: $2.04
$2.10
50-Day Range
$1.79
MA: $2.13
$2.72
52-Week Range
$1.25
Now: $2.04
$4.40
Volume232,757 shs
Average Volume368,013 shs
Market Capitalization$125.22 million
P/E RatioN/A
Dividend YieldN/A
Beta1.48
Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CMRX
CUSIPN/A
Phone919-806-1074

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.22 million
Book Value$3.50 per share

Profitability

Net Income$-69,470,000.00
Net Margins-1,162.96%

Miscellaneous

Employees82
Market Cap$125.22 million
Next Earnings Date3/3/2020 (Estimated)
OptionableOptionable

Receive CMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter.


A Rare Upcoming Change to Bitcoin Could Yield Profits of 2,752% (Ad)


Free Report: In a few months the Bitcoin network will undergo a major change that will make it more scarce than ever before. Historically, this event has been correlated to a major price increase.

Chimerix (NASDAQ:CMRX) Frequently Asked Questions

What is Chimerix's stock symbol?

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

How were Chimerix's earnings last quarter?

Chimerix Inc (NASDAQ:CMRX) posted its quarterly earnings data on Tuesday, November, 5th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.22) by $0.07. The biopharmaceutical company had revenue of $1.96 million for the quarter, compared to analysts' expectations of $1.30 million. Chimerix had a negative return on equity of 38.75% and a negative net margin of 1,162.96%. View Chimerix's Earnings History.

When is Chimerix's next earnings date?

Chimerix is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Chimerix.

What price target have analysts set for CMRX?

3 Wall Street analysts have issued 12-month price targets for Chimerix's stock. Their forecasts range from $2.00 to $7.00. On average, they expect Chimerix's share price to reach $4.00 in the next year. This suggests a possible upside of 96.1% from the stock's current price. View Analyst Price Targets for Chimerix.

What is the consensus analysts' recommendation for Chimerix?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Chimerix.

Has Chimerix been receiving favorable news coverage?

News headlines about CMRX stock have been trending negative recently, according to InfoTrie. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Chimerix earned a news impact score of -2.0 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Chimerix.

Are investors shorting Chimerix?

Chimerix saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 1,170,000 shares, an increase of 11.4% from the December 15th total of 1,050,000 shares. Based on an average daily trading volume, of 801,400 shares, the days-to-cover ratio is presently 1.5 days. Approximately 2.6% of the shares of the company are short sold. View Chimerix's Current Options Chain.

Who are some of Chimerix's key competitors?

What other stocks do shareholders of Chimerix own?

Who are Chimerix's key executives?

Chimerix's management team includes the folowing people:
  • Mr. Timothy W. Trost, Sr. VP, CFO & Corp. Sec. (Age 61)
  • Dr. William Garrett Nichols M.D., MS, Chief Medical Officer (Age 50)
  • Mr. Michael A. Sherman, CEO & Pres (Age 53)
  • Dr. Roy W. Ware Ph.D., MBA, Chief Manufacturing & Technology Officer
  • Dr. Randall Lanier Ph.D., Chief Science Officer

How do I buy shares of Chimerix?

Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Chimerix's stock price today?

One share of CMRX stock can currently be purchased for approximately $2.04.

How big of a company is Chimerix?

Chimerix has a market capitalization of $125.22 million and generates $7.22 million in revenue each year. The biopharmaceutical company earns $-69,470,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. Chimerix employs 82 workers across the globe.View Additional Information About Chimerix.

What is Chimerix's official website?

The official website for Chimerix is http://www.chimerix.com/.

How can I contact Chimerix?

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-806-1074 or via email at [email protected]


MarketBeat Community Rating for Chimerix (NASDAQ CMRX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  331 (Vote Outperform)
Underperform Votes:  349 (Vote Underperform)
Total Votes:  680
MarketBeat's community ratings are surveys of what our community members think about Chimerix and other stocks. Vote "Outperform" if you believe CMRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CMRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel